Symbols / RNA Stock $13.85 +1.39% Atrium Therapeutics, Inc.

Healthcare • Biotechnology • United States • NMS
RNA (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
About

Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company's development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for the treatment of PRKAG2 syndrome; and ATR 1086, a siRNA-based therapy targeting PLN for the treatment of PLN cardiomyopathy. It also focuses on pipeline to treat a range of genetic and cardiac diseases. The company was incorporated in 2025 and is headquartered in San Diego, California.

Stock Fundamentals
Scroll to Statements
Market Cap 214.88M Enterprise Value — Income -49.50M Sales 18.62M Book/sh -4.04 Cash/sh —
Dividend Yield — Payout 0.00% Employees — IPO — P/E — Forward P/E -3.43
PEG — P/S 11.54 P/B -3.43 P/C — EV/EBITDA — EV/Sales —
Quick Ratio 0.00 Current Ratio 0.07 Debt/Eq — LT Debt/Eq — EPS (ttm) -4.48 EPS next Y -4.03
EPS Growth — Revenue Growth -71.10% Earnings 2026-05-11 ROA -3.99% ROE — ROIC —
Gross Margin -137.77% Oper. Margin -33.88% Profit Margin -265.88% Shs Outstand 15.51M Shs Float 15.04M Short Float —
Short Ratio 1.88 Short Interest — 52W High 16.77 52W Low 11.95 Beta — Avg Volume 1.00M
Volume 492.24K Target Price $25.00 Recom None Prev Close $13.66 Price $13.85 Change 1.39%
Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$25.00
Mean price target
2. Current target
$13.85
Latest analyst target
3. DCF / Fair value
$-13.52
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$13.85
Low
$25.00
High
$25.00
Mean
$25.00

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-03-11 init Wells Fargo — → Overweight $25
2025-11-11 main Chardan Capital Neutral → Neutral $72
2025-10-29 down TD Cowen Buy → Hold $74
2025-10-28 down Chardan Capital Buy → Neutral $72
2025-10-28 down RBC Capital Outperform → Sector Perform $72
2025-10-27 down Citigroup Buy → Neutral $72
2025-10-27 down Leerink Partners Outperform → Market Perform $72
2025-10-27 down Raymond James Strong Buy → Market Perform —
2025-10-27 down Bernstein Outperform → Market Perform $72
2025-10-27 down Needham Buy → Hold $65
2025-10-27 down HC Wainwright & Co. Buy → Neutral $72
2025-09-22 main Evercore ISI Group Outperform → Outperform $65
2025-09-17 init Roth Capital — → Buy $62
2025-09-15 main B of A Securities Buy → Buy $65
2025-09-12 main HC Wainwright & Co. Buy → Buy $87
2025-09-10 main Needham Buy → Buy $65
2025-09-10 main Chardan Capital Buy → Buy $75
2025-08-08 main Wells Fargo Overweight → Overweight $75
2025-08-08 main Barclays Overweight → Overweight $62
2025-08-08 main Chardan Capital Buy → Buy $75
News
RSS: Latest RNA news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-01-21 LEVIN ARTHUR A. Director — 1,758 $72.45 $127,367
2026-01-21 MACLEAN MICHAEL F. Chief Financial Officer — 4,542 $72.45 $329,068
2026-01-21 BOYCE SARAH Chief Executive Officer — 14,387 $72.45 $1,042,338
2026-01-21 HUGHES STEVEN GEORGE Officer — 4,895 $72.45 $354,643
2026-01-21 FLANAGAN WILLIAM MICHAEL Officer — 6,534 $72.45 $473,388
2026-01-21 MCCARTHY TERESA Officer — 2,929 $72.45 $212,206
2026-01-07 MACLEAN MICHAEL F. Chief Financial Officer — 1,974 $72.23 $142,582
2026-01-07 MORIARTY JOHN B Officer — 2,374 $72.23 $171,474
2026-01-07 BOYCE SARAH Chief Executive Officer — 8,576 $72.23 $619,444
2026-01-07 HUGHES STEVEN GEORGE Officer — 2,373 $72.23 $171,402
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31
Total Revenue
18.62
+70.85%
10.90
+11.60%
9.76
Operating Revenue
18.62
+70.85%
10.90
+11.60%
9.76
Operating Expense
95.43
+295.74%
24.11
+49.32%
16.15
Research And Development
53.76
+179.99%
19.20
+51.73%
12.65
Selling General And Administration
41.68
+747.76%
4.92
+40.58%
3.50
General And Administrative Expense
41.68
+747.76%
4.92
+40.58%
3.50
Other Gand A
41.68
+747.76%
4.92
+40.58%
3.50
Total Expenses
95.43
+295.74%
24.11
+49.32%
16.15
Operating Income
-76.81
-481.13%
-13.22
-106.98%
-6.39
Total Operating Income As Reported
-76.81
-481.13%
-13.22
-106.98%
-6.39
EBITDA
-76.49
-486.32%
-13.05
-108.80%
-6.25
Normalized EBITDA
-76.49
-486.32%
-13.05
-108.80%
-6.25
Reconciled Depreciation
0.32
+87.79%
0.17
+24.64%
0.14
EBIT
-76.81
-481.13%
-13.22
-106.98%
-6.39
Net Income
-76.68
-205.25%
-25.12
-293.45%
-6.38
Pretax Income
-76.83
-481.31%
-13.22
-106.99%
-6.38
Other Income Expense
-0.01
-700.00%
0.00
+100.00%
0.00
Other Non Operating Income Expenses
-0.01
-700.00%
0.00
+100.00%
0.00
Tax Provision
-0.14
-101.19%
11.91
0.00
Tax Rate For Calcs
0.00
-98.57%
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-76.68
-205.25%
-25.12
-293.45%
-6.38
Net Income From Continuing Operation Net Minority Interest
-76.68
-205.25%
-25.12
-293.45%
-6.38
Net Income From Continuing And Discontinued Operation
-76.68
-205.25%
-25.12
-293.45%
-6.38
Net Income Continuous Operations
-76.68
-205.25%
-25.12
-293.45%
-6.38
Normalized Income
-76.68
-205.25%
-25.12
-293.45%
-6.38
Net Income Common Stockholders
-76.68
-205.25%
-25.12
-293.45%
-6.38
Diluted EPS
-4.48
-205.19%
-1.47
-293.45%
-0.37
Basic EPS
-4.48
-205.19%
-1.47
-293.45%
-0.37
Basic Average Shares
17.11
+0.00%
17.11
+0.00%
17.11
Diluted Average Shares
17.11
-0.06%
17.12
+0.00%
17.12
Diluted NI Availto Com Stockholders
-76.68
-205.25%
-25.12
-293.45%
-6.38
Line Item Trend 2025-12-31 2024-12-31 2023-12-31
Total Assets
278.35
+3773.55%
7.19
-30.19%
10.29
Current Assets
272.85
+56389.65%
0.48
-43.57%
0.86
Cash Cash Equivalents And Short Term Investments
270.00
—
—
Cash And Cash Equivalents
270.00
—
—
Receivables
—
0.00
-100.00%
0.75
Accounts Receivable
—
0.00
-100.00%
0.75
Prepaid Assets
1.53
+217.81%
0.48
+360.00%
0.10
Other Current Assets
1.31
—
—
Total Non Current Assets
5.51
-17.83%
6.70
-28.97%
9.44
Net PPE
5.51
-17.83%
6.70
-28.97%
9.44
Gross PPE
8.35
+5.23%
7.94
-23.11%
10.32
Accumulated Depreciation
-2.84
-130.47%
-1.23
-39.44%
-0.89
Properties
0.00
0.00
0.00
Machinery Furniture Equipment
1.77
0.00
—
Other Properties
6.58
-13.96%
7.65
-23.77%
10.03
Leases
0.00
-100.00%
0.29
+0.00%
0.29
Total Liabilities Net Minority Interest
71.07
+4.06%
68.29
-15.59%
80.91
Current Liabilities
41.80
+55.96%
26.80
-20.71%
33.80
Payables And Accrued Expenses
13.34
+673.51%
1.73
+49.61%
1.15
Payables
4.40
+726.69%
0.53
+6.83%
0.50
Accounts Payable
4.40
+726.69%
0.53
+6.83%
0.50
Current Accrued Expenses
8.95
+649.79%
1.19
+82.14%
0.66
Pensionand Other Post Retirement Benefit Plans Current
3.15
+1179.27%
0.25
-70.99%
0.85
Current Debt And Capital Lease Obligation
3.67
-4.47%
3.84
+5.63%
3.64
Current Capital Lease Obligation
3.67
-4.47%
3.84
+5.63%
3.64
Current Deferred Liabilities
21.64
+3.11%
20.99
-25.47%
28.16
Current Deferred Revenue
21.64
+3.11%
20.99
-25.47%
28.16
Total Non Current Liabilities Net Minority Interest
29.27
-29.47%
41.49
-11.93%
47.11
Long Term Debt And Capital Lease Obligation
—
2.96
-52.41%
6.21
Long Term Capital Lease Obligation
—
2.96
-52.41%
6.21
Non Current Deferred Liabilities
28.69
-24.42%
37.96
-7.18%
40.90
Non Current Deferred Revenue
28.69
-24.42%
37.96
-7.18%
40.90
Other Non Current Liabilities
0.57
+0.00%
0.57
—
Stockholders Equity
207.29
+439.21%
-61.11
+13.47%
-70.62
Common Stock Equity
207.29
+439.21%
-61.11
+13.47%
-70.62
Capital Stock
0.02
—
—
Common Stock
0.02
—
—
Share Issued
15.51
+0.00%
15.51
+0.00%
15.51
Ordinary Shares Number
15.51
+0.00%
15.51
+0.00%
15.51
Additional Paid In Capital
207.27
—
—
Total Equity Gross Minority Interest
207.29
+439.21%
-61.11
+13.47%
-70.62
Total Capitalization
207.29
+439.21%
-61.11
+13.47%
-70.62
Working Capital
231.04
+977.86%
-26.32
+20.11%
-32.95
Invested Capital
207.29
+439.21%
-61.11
+13.47%
-70.62
Total Debt
3.67
-46.01%
6.80
-30.97%
9.85
Capital Lease Obligations
3.67
-46.01%
6.80
-30.97%
9.85
Net Tangible Assets
207.29
+439.21%
-61.11
+13.47%
-70.62
Tangible Book Value
207.29
+439.21%
-61.11
+13.47%
-70.62
Other Equity Interest
—
-61.11
+13.47%
-70.62
Line Item Trend 2025-12-31 2024-12-31 2023-12-31
Operating Cash Flow
-41.13
-82.37%
-22.55
-139.99%
56.39
Cash Flow From Continuing Operating Activities
-41.13
-82.37%
-22.55
-139.99%
56.39
Net Income From Continuing Operations
-49.50
-97.04%
-25.12
-293.45%
-6.38
Depreciation Amortization Depletion
0.32
+87.79%
0.17
+24.64%
0.14
Depreciation
0.32
+87.79%
0.17
+24.64%
0.14
Depreciation And Amortization
0.32
+87.79%
0.17
+24.64%
0.14
Other Non Cash Items
0.57
+180.39%
0.20
—
Stock Based Compensation
7.68
+141.71%
3.18
+26.73%
2.51
Deferred Tax
-0.14
-101.19%
11.91
0.00
Deferred Income Tax
-0.14
-101.19%
11.91
0.00
Operating Gains Losses
0.14
-31.37%
0.20
+4.62%
0.20
Gain Loss On Sale Of PPE
0.14
0.00
-100.00%
0.20
Change In Working Capital
-0.20
+98.45%
-12.89
-121.51%
59.94
Change In Receivables
0.00
-100.00%
0.75
-45.82%
1.39
Changes In Account Receivables
0.00
-100.00%
0.75
-45.82%
1.39
Change In Prepaid Assets
-1.05
-178.31%
-0.38
-447.83%
-0.07
Change In Payables And Accrued Expense
14.18
+47363.33%
-0.03
+96.41%
-0.84
Change In Accrued Expense
10.45
+16429.69%
-0.06
+91.90%
-0.79
Change In Payable
3.73
+10864.71%
0.03
+173.91%
-0.05
Change In Account Payable
3.73
+10864.71%
0.03
+173.91%
-0.05
Change In Other Working Capital
-12.02
+12.96%
-13.81
-123.22%
59.45
Change In Other Current Assets
-1.31
0.00
—
Change In Other Current Liabilities
0.00
-100.00%
0.57
0.00
Investing Cash Flow
-1.45
-443.23%
-0.27
+16.88%
-0.32
Cash Flow From Continuing Investing Activities
-1.45
-443.23%
-0.27
+16.88%
-0.32
Net PPE Purchase And Sale
-1.45
-443.23%
-0.27
+16.88%
-0.32
Purchase Of PPE
-1.45
-443.23%
-0.27
+16.88%
-0.32
Capital Expenditure
-1.45
-443.23%
-0.27
+16.88%
-0.32
Financing Cash Flow
42.57
+86.57%
22.82
+140.70%
-56.07
Cash Flow From Continuing Financing Activities
42.57
+86.57%
22.82
+140.70%
-56.07
Net Other Financing Charges
42.57
+86.57%
22.82
+140.70%
-56.07
Beginning Cash Position
0.00
0.00
0.00
End Cash Position
0.00
0.00
0.00
Free Cash Flow
-42.57
-86.57%
-22.82
-140.70%
56.07
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category